Compare Travere Therapeutics Inc. Common Stock (TVTX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs WD 40 Company — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while WD 40 Company trades at $203.62 (market cap $2.74B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and WD 40 Company pays a 2% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and WD 40 Company for 23 Days on average.
| TVTX | WDFC | |
|---|---|---|
Market Cap | $4.88B | $2.74B |
Volume | 1,668,577 | 121,880 |
Sector | Health | Basic Materials |
52-Week High | $67.52 | $264.91 |
52-Week Low | $26.79 | $187.52 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $5.01B | $2.80B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
WDFC trades at $204.41, up 0.8% today, with a bullish technical signal from moving averages and key resistance at $206. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.33, and maintains robust profitability with a 33.22% ROE. Recent news highlights strategic growth initiatives and institutional buying interest.
Outlook is mixed; solid fundamentals and growth strategy support upside, but high valuation (P/E 31.07) and margin pressures from input costs pose risks. Analyst consensus is cautious with 71% hold ratings, indicating tempered expectations despite operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
